SlideShare une entreprise Scribd logo
1  sur  33
ANTIDEPRESSANTS
Samaiya Mushtaq
CHEM 5398
DEPRESSION
 Types
 Symptoms
 Diagnosis
 Causes
 Treatment
TYPES OF DEPRESSION
 Major depression
 Chronic depression (Dysthymia)
 Atypical depression
 Bipolar disorder/Manic depression
 Seasonal depression (SAD)
SYMPTOMS
 persistently sad, anxious, or empty moods
 loss of pleasure in usual activities (anhedonia)
 feelings of helplessness, guilt, or worthlessness
 crying, hopelessness, or persistent pessimism
 fatigue or decreased energy
 loss of memory, concentration, or decision-making capability
 restlessness, irritability
 sleep disturbances
 change in appetite or weight
 physical symptoms that defy diagnosis and do not respond to
treatment (especially pain and gastrointestinal complaints)
 thoughts of suicide or death, or suicide attempts
 poor self-image or self-esteem (as illustrated, for example, by
verbal self-reproach)
DIAGNOSIS
 Extensive patient and family history
 Blood test for hypothyroidism
 Current medication
 DSM-IV
 One of the first two symptoms
 Five other symptoms
CAUSES OF DEPRESSION
 Genetics
 Death/Abuse
 Medications
TREATMENT FOR DEPRESSION
 Psychotherapy
 Electroconvulsive therapy
 Natural alternatives
 Medication
 SSRIs
 MAOIs
 TCAs
 SNRIs
 NDRIs
 TeCAs
NEUROTRANSMITTERS AND THE
CATECHOLAMINE HYPOTHESIS
 Neurotransmitters pass along signal
 Smaller amount of neurotransmitters causes
depression
MONOAMINE OXIDASE (MAO) AND
DEPRESSION
 MAO catalyze deamination of intracellular
monoamines
 MAO-A oxidizes epinephrine, norepinephrine, serotonin
 MAO-B oxidizes phenylethylamine
 Both oxidize dopamine nonpreferentially
 MAO transporters reuptake extracellular
monoamine
MONOAMINE OXIDASE INHIBITORS
(MAOIS)
 History
 Isoniazid
 Iproniazid
 Current Drugs
 Mechanism of Action
 Side Effects Isoniazid
Iproniazid
MAOIS ON THE MARKET
 MAO Inhibitors (nonselective)
 Phenelzine (Nardil)
 Tranylcypromine (Parnate)
 Isocarboxazid (Marplan)
 MAO-B Inhibitors (selective for MAO-B)
 Selegiline (Emsam)
MAOIS MECHANISM OF ACTION
 MAO contains a
cysteinyl-linked
flavin
 MAOIs covalently
bind to N-5 of the
flavin residue of
the enzyme
MAOIS SIDE EFFECTS
 Drowsiness/Fatigue
 Constipation
 Nausea
 Diarrhea
 Dizziness
 Low blood pressure
 Lightheadedness,
 Decreased urine output
 Decreased sexual
function
 Sleep disturbances
 Muscle twitching
 Weight gain
 Blurred vision
 Headache
 Increased appetite
 Restlessness
 Shakiness
 Weakness
 Increased sweating
MAOIS SIDE EFFECTS
 Side effects have put MAOIs in the second or third
line of defense despite superior efficacy
 MAO-A inhibitors interfere with breakdown of
tyramine
 High tyramine levels cause hypertensive crisis (the
“cheese effect”)
 Can be controlled with restricted diet
 MAOIs interact with certain drugs
 Serotonin syndrome (muscle rigidity, fever, seizures)
 Pain medications and SSRIs must be avoided
THE RECEPTOR SENSITIVITY
HYPOTHESIS
 Supersensitivity and up-regulation of post-synaptic
receptors leads to depression
 Suicidal and depressed patients have increased
5HT-α2 receptors
TRICYCLIC ANTIDEPRESSANTS (TCAS)
 History
 Imipramine
 Current Drugs
 Mechanism of Action
 Side Effects
Imipramine
TCAS ON THE MARKET
 Amitriptyline
 Desipramine (Norpramin)
 Doxepin (Sinequan)
 Imipramine (Tofranil, Tofranil-PM)
 Nortriptyline (Pamelor)
 Protriptyline (Vivactil)
 Trimipramine (Surmontil)
TCAS MECHANISM OF ACTION
 TCAs inhibit serotonin,
norepinephrine, and dopamine
transporters, slowing reuptake
 TCAs also allow for the
downregulation of post-synaptic
receptors
 All TCAs and SSRIs contain an
essential amino group that
appears to interact with Asp-98
in hSERT
TCAS SIDE EFFECTS
 Muscarinic M1 receptor antagonism - anticholinergic
effects including dry mouth, blurred vision, constipation,
urinary retention and impotence
 Histamine H1 receptor antagonism - sedation and
weight gain
 Adrenergic α receptor antagonism - postural
hypotension
 Direct membrane effects - reduced seizure threshold,
arrhythmia
 Serotonin 5-HT2 receptor antagonism - weight gain (and
reduced anxiety)
TCAS SIDE EFFECTS
 Nonselectivity results in
greater side effects
 TCAs can also lead to
cardiotoxicity
 Increased LDH leakage
 Slow cardiac conduction
 High potency can lead to
mania
 Contraindicated with persons
with bipolar disorder or manic
depression
TETRACYCLIC ANTIDEPRESSANTS
(TECAS)
 Current Drugs
 Mirtazapine (Remeron)
 Mechanism of Action
 Same as TCAs
 Side Effects
SELECTIVE SEROTONIN REUPTAKE
INHIBITORS
 Most commonly prescribed class
 Current drugs
 Mechanism of action
 Side effects
Serotonin
SSRIS ON THE MARKET
 citalopram (Celexa)
 dapoxetine (Priligy)
 escitalopram (Lexapro)
 fluoxetine (Prozac)
 fluvoxamine (Luvox)
 paroxetine (Paxil)
 sertraline (Zoloft)
 zimelidine (Zelmid) (discontinued)
 indalpine (Upstene) (discontinued)
Fluoxetine 1:1
Sertraline
SSRIS MECHANISM OF ACTION
 Exact mechanism remains uncertain
 Ser-438 residue in the human serotonin transporter
(hSERT) appears to be a determining factor in
SSRI potency
 Antidepressants interact directly with hSERT
 http://www.mayoclinic.com/health/antidepressants/
MM00660
SSRIS SIDE EFFECTS
 Anhedonia
 Apathy
 Nausea/vomiting
 Drowsiness or
somnolence
 Headache
 Bruxism (involuntarily
grinding of the teeth)
 Extremely vivid and
strange dreams
 Dizziness
 Fatigue
 Changes in sexual
behavior
 Suicidal thoughts
SSRIS SIDE EFFECTS
 Many disappear within 4 weeks (adaption phase)
 Side effects more manageable compared to MAOIs
and TCAs
 Sexual side effects are common
 SSRI cessation syndrome
 Brain zaps
 Sexual dysfunction
SEROTONIN-NOREPINEPHRINE
REUPTAKE INHIBITORS (SNRIS)
 Slightly greater efficacy than SSRIs
 Slightly fewer adverse effects than SSRIs
 Current drugs
 Venlafaxine (Effexor)
 Duloxetine (Cymbalta)
 Mechanism of Action
 Very similar to SSRIs
 Works on both neurotransmitters
 Side effects
 Similar to SSRIs
 Suicide
Venlafaxine 1:1
Duloxetine
NOREPINEPHRINE-DOPAMINE
REUPTAKE INHIBITORS (NDRIS)
 Current drugs
 Bupropion (Wellbutrin)
 Mechanims of Action
 Similar to SSRIs and SNRIs
 More potent in inhibiting dopamine
 Also anα3-β4 nicotinic antagonist
 Adverse effects
 Lowers seizure threshold
 Suicide
 Does not cause weight gain or sexual dysfunction (even
used to treat the two)
Bupropion 1:1
ASSIGNED READING
 An Introduction to Medicinal Chemistry, by Graham
L. Patrick, Chapter 20, pp. 593-8.
 Kelly, John. Novel therapeutic targets for the
treatment of depression. Current Medicinal
Chemistry: Central Nervous System Agents (2003),
3(4), 311-322.
Optional Reading:
Wong, David T.; Perry, Kenneth W.; Bymaster, Frank P. Case
History: The Discovery of Fluoxetine Hydrochloride (Prozac).
Nature Reviews Drug Discovery (2005), 4(9), 764-774.
Krishnan, K. Ranga. Revisiting monoamine oxidase inhibitors.
Journal of Clinical Psychiatry (Memphis, TN, United States)
(2007), 68(Suppl. 8), 35-41.
HOMEWORK QUESTIONS
1. Many of the medications to treat depression are thought to involve systems
utilizing the monoamine neurotransmitters, noradrenaline, dopamine, and
serotonin (5-HT). Draw the structures of these neurotransmitters. Why are
they called monoamines? Illustrate their structural resemblance to one
another.
2. Monoamine oxidase inhibitors (MAOIs) increase CNS synaptic concentrations
of these monoamines by inhibiting an enzyme responsible for their
degradation. Draw the reaction scheme for the biological degradation of
noradrenaline by monoamine oxidase.
3. Illustrate how the TCAs and SSRIs might resemble the monoamine
neurotransmitters, providing one example of each class of antidepressant.
REFERENCES
 http://ajp.psychiatryonline.org/cgi/reprint/157/11/1901
 http://www.webmd.com/depression/
 http://pn.psychiatryonline.org/content/41/24/21.full
 http://www.mayoclinic.com/health/maois/MH00072
 http://www.springerlink.com/content/b9b8668ff59f89d7/fulltext.pdf
 http://www.emsam.com/pi_emsam.pdf
 http://www.nevdgp.org.au/info/topics/depression_theory.htm
 http://www.uspharmacist.com/content/t/psychotropic_disorders/c/11467/
 http://www.jbc.org/content/284/15/10276.full.pdf+html
 http://www.aafp.org/afp/981200ap/cadieux.html
 http://www.mayoclinic.com/health/antidepressants/MH00071
 http://books.google.com/books?id=R0W1ErpsQpkC&pg=PA565&lpg=PA565&dq=tcas+mechanism+of+a
ction&source=bl&ots=oASle2Z-
pr&sig=36CB_3JY4uD3LIYvqXWmAb3nliY&hl=en&ei=HzfFS9OrB4Tu9gTD6_ixDg&sa=X&oi=book_res
ult&ct=result&resnum=8&ved=0CCoQ6AEwBw#v=onepage&q=tcas%20mechanism%20of%20action&f
=false
 http://www.informaworld.com/smpp/content~content=a916036122&db=all

Contenu connexe

Similaire à Antidepressants.ppt

Palazidou 03
Palazidou 03Palazidou 03
Palazidou 03
henkpar
 
Depression & suicide
Depression & suicideDepression & suicide
Depression & suicide
Sarath Menon
 
Hanipsych ssri
Hanipsych  ssriHanipsych  ssri
Hanipsych ssri
Hani Hamed
 
Hanipsych ssri
Hanipsych  ssriHanipsych  ssri
Hanipsych ssri
Hani Hamed
 

Similaire à Antidepressants.ppt (20)

06 Psychotherapeutic Agents Upd
06 Psychotherapeutic Agents Upd06 Psychotherapeutic Agents Upd
06 Psychotherapeutic Agents Upd
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Pharmacology of Antidepressants and its mechanism
Pharmacology of Antidepressants and its mechanismPharmacology of Antidepressants and its mechanism
Pharmacology of Antidepressants and its mechanism
 
Palazidou 03
Palazidou 03Palazidou 03
Palazidou 03
 
antidepressantS-THAMIZH.ppt
antidepressantS-THAMIZH.pptantidepressantS-THAMIZH.ppt
antidepressantS-THAMIZH.ppt
 
Updates on antidepressant medications
Updates on antidepressant medicationsUpdates on antidepressant medications
Updates on antidepressant medications
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
05 antidepressants by ravikiran
05 antidepressants by ravikiran 05 antidepressants by ravikiran
05 antidepressants by ravikiran
 
Pharma Nervous Day 2.pptx
Pharma Nervous Day 2.pptxPharma Nervous Day 2.pptx
Pharma Nervous Day 2.pptx
 
NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)
NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)
NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)
 
Depression & suicide
Depression & suicideDepression & suicide
Depression & suicide
 
Seminar On Antidepressants
Seminar On AntidepressantsSeminar On Antidepressants
Seminar On Antidepressants
 
Antidepressants Update
Antidepressants UpdateAntidepressants Update
Antidepressants Update
 
Anti depressant , antidepressant
Anti depressant , antidepressantAnti depressant , antidepressant
Anti depressant , antidepressant
 
phants
phantsphants
phants
 
Antidepressants. Mood Stabilizers. Psychostimulants
Antidepressants. Mood Stabilizers. PsychostimulantsAntidepressants. Mood Stabilizers. Psychostimulants
Antidepressants. Mood Stabilizers. Psychostimulants
 
Hanipsych ssri
Hanipsych  ssriHanipsych  ssri
Hanipsych ssri
 
Hanipsych ssri
Hanipsych  ssriHanipsych  ssri
Hanipsych ssri
 
anti depressants drugs for mbbs students pharmacology.ppt
anti depressants drugs for mbbs students pharmacology.pptanti depressants drugs for mbbs students pharmacology.ppt
anti depressants drugs for mbbs students pharmacology.ppt
 

Plus de Imtiyaz60

Asthma and COPD PATHOPHYSIOLOGY .pptx
Asthma and COPD PATHOPHYSIOLOGY    .pptxAsthma and COPD PATHOPHYSIOLOGY    .pptx
Asthma and COPD PATHOPHYSIOLOGY .pptx
Imtiyaz60
 
Angina and MI PATHOPHYSIOLOGY .pdf
Angina and MI PATHOPHYSIOLOGY       .pdfAngina and MI PATHOPHYSIOLOGY       .pdf
Angina and MI PATHOPHYSIOLOGY .pdf
Imtiyaz60
 
ATHEROSCLEROSIS pathophysiology .pptx
ATHEROSCLEROSIS pathophysiology    .pptxATHEROSCLEROSIS pathophysiology    .pptx
ATHEROSCLEROSIS pathophysiology .pptx
Imtiyaz60
 
PATHOLOGY OF HYPERTENSION .ppt
PATHOLOGY OF HYPERTENSION           .pptPATHOLOGY OF HYPERTENSION           .ppt
PATHOLOGY OF HYPERTENSION .ppt
Imtiyaz60
 
Hypertension and its pathophysiology.pptx
Hypertension and its pathophysiology.pptxHypertension and its pathophysiology.pptx
Hypertension and its pathophysiology.pptx
Imtiyaz60
 
Appetite-stimulants-Digestants-and-carminatives.pptx
Appetite-stimulants-Digestants-and-carminatives.pptxAppetite-stimulants-Digestants-and-carminatives.pptx
Appetite-stimulants-Digestants-and-carminatives.pptx
Imtiyaz60
 
Anti Ulcer drugs pharmacology and classification
Anti Ulcer drugs pharmacology and classificationAnti Ulcer drugs pharmacology and classification
Anti Ulcer drugs pharmacology and classification
Imtiyaz60
 
gingerasafoetida.pptx
gingerasafoetida.pptxgingerasafoetida.pptx
gingerasafoetida.pptx
Imtiyaz60
 
Tuberculosis.pptx
Tuberculosis.pptxTuberculosis.pptx
Tuberculosis.pptx
Imtiyaz60
 
strokepresentation-170712173032 (1).pptx
strokepresentation-170712173032 (1).pptxstrokepresentation-170712173032 (1).pptx
strokepresentation-170712173032 (1).pptx
Imtiyaz60
 
Thyroid gland.pptx
Thyroid gland.pptxThyroid gland.pptx
Thyroid gland.pptx
Imtiyaz60
 
inflammatory bowel diseas.pptx
inflammatory bowel diseas.pptxinflammatory bowel diseas.pptx
inflammatory bowel diseas.pptx
Imtiyaz60
 
tannins-170116185017.pptx
tannins-170116185017.pptxtannins-170116185017.pptx
tannins-170116185017.pptx
Imtiyaz60
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.ppt
Imtiyaz60
 
tuberculosiscompletednew-170308134731.pptx
tuberculosiscompletednew-170308134731.pptxtuberculosiscompletednew-170308134731.pptx
tuberculosiscompletednew-170308134731.pptx
Imtiyaz60
 
2_2019_10_26!04_54_11_PM.ppt
2_2019_10_26!04_54_11_PM.ppt2_2019_10_26!04_54_11_PM.ppt
2_2019_10_26!04_54_11_PM.ppt
Imtiyaz60
 
Electrophysiology_of_Heart.pptx
Electrophysiology_of_Heart.pptxElectrophysiology_of_Heart.pptx
Electrophysiology_of_Heart.pptx
Imtiyaz60
 
rheumatoidarthritispptbyann-160402080357.pptx
rheumatoidarthritispptbyann-160402080357.pptxrheumatoidarthritispptbyann-160402080357.pptx
rheumatoidarthritispptbyann-160402080357.pptx
Imtiyaz60
 

Plus de Imtiyaz60 (20)

asthma .pptx
asthma                                             .pptxasthma                                             .pptx
asthma .pptx
 
Asthma and COPD PATHOPHYSIOLOGY .pptx
Asthma and COPD PATHOPHYSIOLOGY    .pptxAsthma and COPD PATHOPHYSIOLOGY    .pptx
Asthma and COPD PATHOPHYSIOLOGY .pptx
 
Angina and MI PATHOPHYSIOLOGY .pdf
Angina and MI PATHOPHYSIOLOGY       .pdfAngina and MI PATHOPHYSIOLOGY       .pdf
Angina and MI PATHOPHYSIOLOGY .pdf
 
ATHEROSCLEROSIS pathophysiology .pptx
ATHEROSCLEROSIS pathophysiology    .pptxATHEROSCLEROSIS pathophysiology    .pptx
ATHEROSCLEROSIS pathophysiology .pptx
 
PATHOLOGY OF HYPERTENSION .ppt
PATHOLOGY OF HYPERTENSION           .pptPATHOLOGY OF HYPERTENSION           .ppt
PATHOLOGY OF HYPERTENSION .ppt
 
Hypertension and its pathophysiology.pptx
Hypertension and its pathophysiology.pptxHypertension and its pathophysiology.pptx
Hypertension and its pathophysiology.pptx
 
Appetite-stimulants-Digestants-and-carminatives.pptx
Appetite-stimulants-Digestants-and-carminatives.pptxAppetite-stimulants-Digestants-and-carminatives.pptx
Appetite-stimulants-Digestants-and-carminatives.pptx
 
Anti Ulcer drugs pharmacology and classification
Anti Ulcer drugs pharmacology and classificationAnti Ulcer drugs pharmacology and classification
Anti Ulcer drugs pharmacology and classification
 
gingerasafoetida.pptx
gingerasafoetida.pptxgingerasafoetida.pptx
gingerasafoetida.pptx
 
leprosy.pptx
leprosy.pptxleprosy.pptx
leprosy.pptx
 
Tuberculosis.pptx
Tuberculosis.pptxTuberculosis.pptx
Tuberculosis.pptx
 
strokepresentation-170712173032 (1).pptx
strokepresentation-170712173032 (1).pptxstrokepresentation-170712173032 (1).pptx
strokepresentation-170712173032 (1).pptx
 
Thyroid gland.pptx
Thyroid gland.pptxThyroid gland.pptx
Thyroid gland.pptx
 
inflammatory bowel diseas.pptx
inflammatory bowel diseas.pptxinflammatory bowel diseas.pptx
inflammatory bowel diseas.pptx
 
tannins-170116185017.pptx
tannins-170116185017.pptxtannins-170116185017.pptx
tannins-170116185017.pptx
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.ppt
 
tuberculosiscompletednew-170308134731.pptx
tuberculosiscompletednew-170308134731.pptxtuberculosiscompletednew-170308134731.pptx
tuberculosiscompletednew-170308134731.pptx
 
2_2019_10_26!04_54_11_PM.ppt
2_2019_10_26!04_54_11_PM.ppt2_2019_10_26!04_54_11_PM.ppt
2_2019_10_26!04_54_11_PM.ppt
 
Electrophysiology_of_Heart.pptx
Electrophysiology_of_Heart.pptxElectrophysiology_of_Heart.pptx
Electrophysiology_of_Heart.pptx
 
rheumatoidarthritispptbyann-160402080357.pptx
rheumatoidarthritispptbyann-160402080357.pptxrheumatoidarthritispptbyann-160402080357.pptx
rheumatoidarthritispptbyann-160402080357.pptx
 

Dernier

1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
QucHHunhnh
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please Practise
AnaAcapella
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
QucHHunhnh
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
KarakKing
 

Dernier (20)

Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please Practise
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 

Antidepressants.ppt

  • 2. DEPRESSION  Types  Symptoms  Diagnosis  Causes  Treatment
  • 3. TYPES OF DEPRESSION  Major depression  Chronic depression (Dysthymia)  Atypical depression  Bipolar disorder/Manic depression  Seasonal depression (SAD)
  • 4. SYMPTOMS  persistently sad, anxious, or empty moods  loss of pleasure in usual activities (anhedonia)  feelings of helplessness, guilt, or worthlessness  crying, hopelessness, or persistent pessimism  fatigue or decreased energy  loss of memory, concentration, or decision-making capability  restlessness, irritability  sleep disturbances  change in appetite or weight  physical symptoms that defy diagnosis and do not respond to treatment (especially pain and gastrointestinal complaints)  thoughts of suicide or death, or suicide attempts  poor self-image or self-esteem (as illustrated, for example, by verbal self-reproach)
  • 5. DIAGNOSIS  Extensive patient and family history  Blood test for hypothyroidism  Current medication  DSM-IV  One of the first two symptoms  Five other symptoms
  • 6. CAUSES OF DEPRESSION  Genetics  Death/Abuse  Medications
  • 7. TREATMENT FOR DEPRESSION  Psychotherapy  Electroconvulsive therapy  Natural alternatives  Medication  SSRIs  MAOIs  TCAs  SNRIs  NDRIs  TeCAs
  • 8. NEUROTRANSMITTERS AND THE CATECHOLAMINE HYPOTHESIS  Neurotransmitters pass along signal  Smaller amount of neurotransmitters causes depression
  • 9. MONOAMINE OXIDASE (MAO) AND DEPRESSION  MAO catalyze deamination of intracellular monoamines  MAO-A oxidizes epinephrine, norepinephrine, serotonin  MAO-B oxidizes phenylethylamine  Both oxidize dopamine nonpreferentially  MAO transporters reuptake extracellular monoamine
  • 10. MONOAMINE OXIDASE INHIBITORS (MAOIS)  History  Isoniazid  Iproniazid  Current Drugs  Mechanism of Action  Side Effects Isoniazid Iproniazid
  • 11. MAOIS ON THE MARKET  MAO Inhibitors (nonselective)  Phenelzine (Nardil)  Tranylcypromine (Parnate)  Isocarboxazid (Marplan)  MAO-B Inhibitors (selective for MAO-B)  Selegiline (Emsam)
  • 12. MAOIS MECHANISM OF ACTION  MAO contains a cysteinyl-linked flavin  MAOIs covalently bind to N-5 of the flavin residue of the enzyme
  • 13.
  • 14. MAOIS SIDE EFFECTS  Drowsiness/Fatigue  Constipation  Nausea  Diarrhea  Dizziness  Low blood pressure  Lightheadedness,  Decreased urine output  Decreased sexual function  Sleep disturbances  Muscle twitching  Weight gain  Blurred vision  Headache  Increased appetite  Restlessness  Shakiness  Weakness  Increased sweating
  • 15. MAOIS SIDE EFFECTS  Side effects have put MAOIs in the second or third line of defense despite superior efficacy  MAO-A inhibitors interfere with breakdown of tyramine  High tyramine levels cause hypertensive crisis (the “cheese effect”)  Can be controlled with restricted diet  MAOIs interact with certain drugs  Serotonin syndrome (muscle rigidity, fever, seizures)  Pain medications and SSRIs must be avoided
  • 16. THE RECEPTOR SENSITIVITY HYPOTHESIS  Supersensitivity and up-regulation of post-synaptic receptors leads to depression  Suicidal and depressed patients have increased 5HT-α2 receptors
  • 17. TRICYCLIC ANTIDEPRESSANTS (TCAS)  History  Imipramine  Current Drugs  Mechanism of Action  Side Effects Imipramine
  • 18. TCAS ON THE MARKET  Amitriptyline  Desipramine (Norpramin)  Doxepin (Sinequan)  Imipramine (Tofranil, Tofranil-PM)  Nortriptyline (Pamelor)  Protriptyline (Vivactil)  Trimipramine (Surmontil)
  • 19. TCAS MECHANISM OF ACTION  TCAs inhibit serotonin, norepinephrine, and dopamine transporters, slowing reuptake  TCAs also allow for the downregulation of post-synaptic receptors  All TCAs and SSRIs contain an essential amino group that appears to interact with Asp-98 in hSERT
  • 20. TCAS SIDE EFFECTS  Muscarinic M1 receptor antagonism - anticholinergic effects including dry mouth, blurred vision, constipation, urinary retention and impotence  Histamine H1 receptor antagonism - sedation and weight gain  Adrenergic α receptor antagonism - postural hypotension  Direct membrane effects - reduced seizure threshold, arrhythmia  Serotonin 5-HT2 receptor antagonism - weight gain (and reduced anxiety)
  • 21. TCAS SIDE EFFECTS  Nonselectivity results in greater side effects  TCAs can also lead to cardiotoxicity  Increased LDH leakage  Slow cardiac conduction  High potency can lead to mania  Contraindicated with persons with bipolar disorder or manic depression
  • 22. TETRACYCLIC ANTIDEPRESSANTS (TECAS)  Current Drugs  Mirtazapine (Remeron)  Mechanism of Action  Same as TCAs  Side Effects
  • 23. SELECTIVE SEROTONIN REUPTAKE INHIBITORS  Most commonly prescribed class  Current drugs  Mechanism of action  Side effects Serotonin
  • 24. SSRIS ON THE MARKET  citalopram (Celexa)  dapoxetine (Priligy)  escitalopram (Lexapro)  fluoxetine (Prozac)  fluvoxamine (Luvox)  paroxetine (Paxil)  sertraline (Zoloft)  zimelidine (Zelmid) (discontinued)  indalpine (Upstene) (discontinued) Fluoxetine 1:1 Sertraline
  • 25. SSRIS MECHANISM OF ACTION  Exact mechanism remains uncertain  Ser-438 residue in the human serotonin transporter (hSERT) appears to be a determining factor in SSRI potency  Antidepressants interact directly with hSERT  http://www.mayoclinic.com/health/antidepressants/ MM00660
  • 26. SSRIS SIDE EFFECTS  Anhedonia  Apathy  Nausea/vomiting  Drowsiness or somnolence  Headache  Bruxism (involuntarily grinding of the teeth)  Extremely vivid and strange dreams  Dizziness  Fatigue  Changes in sexual behavior  Suicidal thoughts
  • 27. SSRIS SIDE EFFECTS  Many disappear within 4 weeks (adaption phase)  Side effects more manageable compared to MAOIs and TCAs  Sexual side effects are common  SSRI cessation syndrome  Brain zaps  Sexual dysfunction
  • 28. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)  Slightly greater efficacy than SSRIs  Slightly fewer adverse effects than SSRIs  Current drugs  Venlafaxine (Effexor)  Duloxetine (Cymbalta)  Mechanism of Action  Very similar to SSRIs  Works on both neurotransmitters  Side effects  Similar to SSRIs  Suicide Venlafaxine 1:1 Duloxetine
  • 29.
  • 30. NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS)  Current drugs  Bupropion (Wellbutrin)  Mechanims of Action  Similar to SSRIs and SNRIs  More potent in inhibiting dopamine  Also anα3-β4 nicotinic antagonist  Adverse effects  Lowers seizure threshold  Suicide  Does not cause weight gain or sexual dysfunction (even used to treat the two) Bupropion 1:1
  • 31. ASSIGNED READING  An Introduction to Medicinal Chemistry, by Graham L. Patrick, Chapter 20, pp. 593-8.  Kelly, John. Novel therapeutic targets for the treatment of depression. Current Medicinal Chemistry: Central Nervous System Agents (2003), 3(4), 311-322. Optional Reading: Wong, David T.; Perry, Kenneth W.; Bymaster, Frank P. Case History: The Discovery of Fluoxetine Hydrochloride (Prozac). Nature Reviews Drug Discovery (2005), 4(9), 764-774. Krishnan, K. Ranga. Revisiting monoamine oxidase inhibitors. Journal of Clinical Psychiatry (Memphis, TN, United States) (2007), 68(Suppl. 8), 35-41.
  • 32. HOMEWORK QUESTIONS 1. Many of the medications to treat depression are thought to involve systems utilizing the monoamine neurotransmitters, noradrenaline, dopamine, and serotonin (5-HT). Draw the structures of these neurotransmitters. Why are they called monoamines? Illustrate their structural resemblance to one another. 2. Monoamine oxidase inhibitors (MAOIs) increase CNS synaptic concentrations of these monoamines by inhibiting an enzyme responsible for their degradation. Draw the reaction scheme for the biological degradation of noradrenaline by monoamine oxidase. 3. Illustrate how the TCAs and SSRIs might resemble the monoamine neurotransmitters, providing one example of each class of antidepressant.
  • 33. REFERENCES  http://ajp.psychiatryonline.org/cgi/reprint/157/11/1901  http://www.webmd.com/depression/  http://pn.psychiatryonline.org/content/41/24/21.full  http://www.mayoclinic.com/health/maois/MH00072  http://www.springerlink.com/content/b9b8668ff59f89d7/fulltext.pdf  http://www.emsam.com/pi_emsam.pdf  http://www.nevdgp.org.au/info/topics/depression_theory.htm  http://www.uspharmacist.com/content/t/psychotropic_disorders/c/11467/  http://www.jbc.org/content/284/15/10276.full.pdf+html  http://www.aafp.org/afp/981200ap/cadieux.html  http://www.mayoclinic.com/health/antidepressants/MH00071  http://books.google.com/books?id=R0W1ErpsQpkC&pg=PA565&lpg=PA565&dq=tcas+mechanism+of+a ction&source=bl&ots=oASle2Z- pr&sig=36CB_3JY4uD3LIYvqXWmAb3nliY&hl=en&ei=HzfFS9OrB4Tu9gTD6_ixDg&sa=X&oi=book_res ult&ct=result&resnum=8&ved=0CCoQ6AEwBw#v=onepage&q=tcas%20mechanism%20of%20action&f =false  http://www.informaworld.com/smpp/content~content=a916036122&db=all

Notes de l'éditeur

  1. Major depression – recurring and disabling. Symptoms must last for at least two weeks and impair one’s ability to interfere with a person's ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Chronic depression – less disabling than major depression, but symptoms can last longer, sometimes being unhappy for two years. More common in women, affects 10.9 million people. Atypical depression, rather than the other two, is characterized less by pervasive sadness and more by overeating, oversleeping, sensitivty to rejection Bipolar/manic depression oscillates between major depression and epsidoes of mania (extreme elation), Bipolar I – episode of mania with or without depression. Bipolar II – episode of depression with episode of hypomania or mania. Seasonal depression (SAD) – often occurs wehre winters are short or there is a big change in the amount of sunlgiht, and often treated with light therapy.
  2. MUST HAVE one of the top two AT LEAST five of the other symptoms Nearly DAILY For at least TWO WEEKS
  3. Doctor will ask many questions about personal mood, new behaviors, changes in routine Check blood and current drugs to rule out other factors (hypothyroidism, drug side effects) Drugs like antihypertensives, oral contraceptives, and Accutane for acne can cause depression BIG THING IS DISRUPTION IN FUNCTIONING
  4. Psycotherapy/talk therapy – especially useful when combined with meds. Goal is to teach good coping skills for every day stressors ECT – electric shock is applied to scalp through electrodes, results in seizure in the brain. Fast and effecitve in patients with depression or suicidal thoughts (good for suicide bc doesn’t have the same delayed onset as meds). Usually given up to three times a week for two to four weeks Natural alternatives – St. John’s wort (sold in teas and tablets, and in diet pills) not good for severe depression but can help mild depression
  5. SYNAPSE: Neurotransmitter passes along synapse from inside storage vesicles through transporters in the presynaptic cell to receptors in the post synaptic cell. Monoamine hypohtesis suggests that small amount of neurotransmitter causes depression
  6. Both early drugs developed in sixties for anti tuberculosis but found to have antidepressant effects, got off market due to toxicity
  7. Phenelzine – major depression Tranylcypromine – major depression Isocarboxazid – major depression Selegiline – comeback of MAOI (MAO-B inhibitor, more selective, loses selectivity at high doses) because no side effects from diet. Used primarily for treatment for Parkinson’s disease (also approved for major depression) – shows significant improvenemnt when taken with L-DOPA
  8. MAOIs bind to the N-5 of the flavin residue if MAO, which prevents MAO from catalyzing the oxidative deamination of the monoamine, increasing their intracellular concentration so more can be released.
  9. Bold ones are most common
  10. Major side effects have kept MAOI use limitied HUGE PITFALL IS DIETARY RESTRICTION Must avoid foods with high levels of tyramine like avocados, bananas, aged cheese, certain meats and wines This is however not seen with selegiline because that is a MAO-B inhibitor, and since tyramine displaces NOREPINEPHRINE from storage vesicles, it effects MAO-A more Serotonin syndrome is caused by drug interactions with herbal weight loss supplement (St John’s wort) and SSRIs and Pain meds like tramadol and meperidine
  11. Imipramine was first tried as an antipsychoti drug for schizophrenia, proved to be insufficient but proved to have antidepressant qualities, in the 50s around the same time as MAOIs. Imipramine is very good for severe depression, but it’s almost too good – also causes hypomania and mania
  12. Side effects have made them second line of defense to SSRIs but they are good for treatment resistant depression bc they are so strong. Amitriptyline – most widely used, most effectve Desipramine – active metabolite of imipramine, used for neuropathic pain Doxepin – used for depression and insomnia Imipramine – used for major depression and enuresis Nortriptyline – same thing Protriptyline – depression UNIQUE BECAUSE IT IS ENERGIZING rather than sedating Trimipramine – depression, insomnia, and pain
  13. Less selective in which cells they target, will prevent serotonin, norepinephrine, and dopamine reuptake
  14. Also first rationally designed drug class, up until the 70s the antidepressants were sort of found by accident Serotonin is also referred to as 5-hydroxytryptamine
  15. More trade names once patent is over but I kept original trade names Citalopram: Major depression Dapoxetine: Premature Ejaculation Escitalopram: Major depression and various other anxiety disorders Fluxoetine: Major depression, OCD, bulimia, etc Fluvoxamine: OCD Paroxetine: Major depression or anxiety Sertraline: Major depression or anxiety Zimelidine had neurological problems like Guillan Barre Indalpine had problems with fetal low WBC
  16. The drug binds in the residue to prevent the presynaptic serotonin transporter from reuptaking the serotonin neurotransmitter. This increases extracellular concentration of serotonin, allowing more messages to be passed along. Over time, this also leads to the downregulation of the postsynaptic receptors so they are fewer and less sensitive, so they more transmittance.
  17. Many side effects go away onec the body gets used to the drug because the drug takes sometime tos tart working Sexual side effects are common (ED, low libido) due to stimuatlion of 5-HT2 receptors leading to less release of dopamine
  18. Venlafaxine is a racemix mixture While SSRIs are less potent than the other classes of drugs, they have more manageable side effects so they’re considered better The mechanism is similar to SSRIs, as are the side effects. However, the rate of suicide for SNRIs has been debateable, especially venlafaxine. Finnish study showed Ven increased suicide risk 1.6 times compared to no treatment while Fluoxetine halved it. FDA study showed 5-fold increase in <25 so it is contraindicated in adolescents.
  19. Bupropion is a racemic mixture